Abstract: The subject invention pertains to compounds and methods of using said compounds to target the multi-functional papain-like protease (PLpro) domain of the viral Nsp3, specifically F0213, F0326, and F0393 that can have broad anti-coronavirus activity, including SARS-CoV-2, MERS-CoV, and coronaviruses hCoV-229E and hCoV-OC43. F0213, F0326, and F0393 can possess a dual therapeutic functionality that suppress CoV replication via blocking viral polyprotein cleavage, as well as promote antiviral immunity by antagonizing the PLpro deubiquitinase activity.

Abstract: Methods and compositions for treating a coronavirus infection in a subject are provided. Also provided are methods and compositions for preventing or treating a coronavirus-associated disease in a subject. The methods and compositions include administering a pharmaceutical composition containing an effective amount of a caspase-6 inhibitor to a subject. The amount of the caspase-6 inhibitor contained in the pharmaceutical composition is effective to reduce replication of the coronavirus in the subject. The disclosed methods and compositions ameliorate lung pathology associated with the coronavirus infection and increases survival in the subject.

Abstract: Enteroviruses, such as EV-A71, have been found to utilize hWARS as a cell surface receptor, with expression ofhWARS rendering cells susceptible to enteroviral infection. Reduction in hWARS cell surface activity reduces susceptibility to enteroviral infection and provides a mode for treatment or prevention of enteroviral infection and its sequelae. Similarly, expression of hWARS in cultured cells and animal models provides models for understanding enteroviral disease mechanisms and the development of vaccines and/or pharmaceuticals for preventing or treating enteroviral disease.

Abstract: Provided a nucleic acid probe or primer for the detection of SARS-CoV-2 RdRp/Helicase, Spike (S) or Nucleocapsid (N), and its use in a method of detecting SARS-CoV-2 in a sample. The nucleic acid probe or primer is consisting of a nucleic acid sequence of any of SEQ ID NOs: 1-12.

Abstract: The subject invention pertains to compounds and methods of using said compounds to target the multi-functional papain-like protease (PLpro) domain of the viral Nsp3, specifically F0213, F0326, and F0393 that can have broad anti-coronavirus activity, including SARS-CoV-2, MERS-CoV, and coronaviruses hCoV-229E and hCoV-OC43. F0213, F0326, and F0393 can possess a dual therapeutic functionality that suppress CoV replication via blocking viral polyprotein cleavage, as well as promote antiviral immunity by antagonizing the PLpro deubiquitinase activity.

Abstract: Methods and compounds for preventing and/or treating Zika virus (ZIKA) infection. And methods to screen for compound to prevent or treat Zika virus infection.

Abstract: Methods and compounds for preventing and/or treating Zika virus(ZIKA) infection. And methods to screen for compound to prevent or treat Zika virus infection.

Abstract: AM580 and structurally related compounds have been found to be useful in treating infection by a wide range of RNA and DNA viruses, and also in reducing associated inflammation. This activity is independent of RAR-? signaling, and is not a result of activation of the hosts innate immune response.

Abstract: Miltefosine is utilized to enhance immune response to vaccination, for example an influenza and/or coronavirus vaccination. The inventive subject matter also provides compositions and methods for enhancing viral yield in cultured cells, by application of a cannabinoid receptor agonist (such as methanandamide) to such cells. Such enhanced viral yield can be used to enhance virus production for purposes of vaccine formulation and/or to improve sensitivity of cell-based virus assays.

Abstract: Enteroviruses, such as EV-A71, have been found to utilize hWARS as a cell surface receptor, with expression ofhWARS rendering cells susceptible to enteroviral infection. Reduction in hWARS cell surface activity reduces susceptibility to enteroviral infection and provides a mode for treatment or prevention of enteroviral infection and its sequelae. Similarly, expression of hWARS in cultured cells and animal models provides models for understanding enteroviral disease mechanisms and the development of vaccines and/or pharmaceuticals for preventing or treating enteroviral disease.

Abstract: Therapy for influenza using a combination of a neuraminidase inhibitor, a macrolide antibiotic, and a non-steroidal anti-inflammatory drug has been found to provide improved clinical outcomes and reduced incidence of viral quasispecies compared to conventional treatment with neuraminidase inhibitors alone. Effective treatment schedules are also provided. The drug combination can be used in concert with a proton-pump inhibitor and/or an additional antibacterial antibiotic.

Abstract: Highly conserved, short untranslated leader sequences have been identified in MERS-CoV and other human pathogenic Coronaviruses that provide the basis for highly sensitive and accurate assays for these viruses. Use of locked nucleic acids is shown to be useful in amplification reactions for these short sequences. RT-PCR using locked nucleic acids is shown to provide accurate detection of a variety of human pathogen Coronaviruses present at 10 copies per reaction or less.